BCAX (Bicara Therapeutics) Debt-to-Equity: 0.00 (As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $29.68
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Debt-to-Equity?

Bicara Therapeutics BCAX +2.38% 12 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 964 Biotechnology companies, Bicara Therapeutics ranks worse than 103734.34% on this metric.

Bicara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.14 Mil. Bicara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.30 Mil. Bicara Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $513.96 Mil. Bicara Therapeutics's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bicara Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 4 years, the highest Debt-to-Equity Ratio of Bicara Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.

BCAX's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Bicara Therapeutics  (NAS:BCAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bicara Therapeutics Debt-to-Equity Related Terms

Bicara Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Debt-to-Equity Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
0.00 -0.00 0.00 0.00

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.00 0.00

BCAX vs ZYME, SRPT, INVA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Bicara Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Debt-to-Equity falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bicara Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.117 + 0.593) / 401.452
=0.00

Bicara Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.14 + 0.301) / 513.958
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Bicara Therapeutics (BCAX) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #999999 out of 964 companies in the Biotechnology industry.
Is Bicara Therapeutics' Debt-to-Equity too high?
Bicara Therapeutics' current Debt-to-Equity is 0.00. Based on the distribution chart, Bicara Therapeutics ranks #999999 out of 964 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Debt-to-Equity compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #999999 out of 964 companies for Debt-to-Equity. This places Bicara Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bicara Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.68
Price